CanBas Co., Ltd. (TYO:4575)

Japan flag Japan · Delayed Price · Currency is JPY
1,032.00
-28.00 (-2.64%)
May 2, 2025, 12:45 PM JST
121.94%
Market Cap 20.26B
Revenue (ttm) n/a
Net Income (ttm) -1.30B
Shares Out 19.11M
EPS (ttm) -70.71
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 162,900
Average Volume 286,750
Open 1,054.00
Previous Close 1,060.00
Day's Range 1,022.00 - 1,066.00
52-Week Range 432.00 - 1,512.00
Beta -1.30
RSI 59.07
Earnings Date May 13, 2025

About CanBas

CanBas Co., Ltd., a clinical stage biopharmaceutical company, develops therapeutics for cancer patients. It develops CBP501, a calmodulin-modulating peptide to treat various cancer; and CBS9106, a reversible exportin-1inhibitor that is in Phase I clinical trial for the treatment of solid tumors. The company has a collaboration alliance with Stemline Therapeutics, Inc. CanBas Co., Ltd. was incorporated in 2000 and is based in Numazu, Japan. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2000
Employees 11
Stock Exchange Tokyo Stock Exchange
Ticker Symbol 4575
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.